| HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation K Takezawa, V Pirazzoli, ME Arcila, CA Nebhan, X Song, E de Stanchina, ... Cancer discovery 2 (10), 922-933, 2012 | 744 | 2012 |
| Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer J Wolf, T Seto, JY Han, N Reguart, EB Garon, HJM Groen, DSW Tan, ... New England Journal of Medicine 383 (10), 944-957, 2020 | 701 | 2020 |
| Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC AO Walter, RTT Sjin, HJ Haringsma, K Ohashi, J Sun, K Lee, ... Cancer discovery 3 (12), 1404-1415, 2013 | 701 | 2013 |
| Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020 | 666 | 2020 |
| Optimization of dosing for EGFR-mutant non–small cell lung cancer with evolutionary cancer modeling J Chmielecki, J Foo, GR Oxnard, K Hutchinson, K Ohashi, R Somwar, ... Science translational medicine 3 (90), 90ra59-90ra59, 2011 | 589 | 2011 |
| Epidermal growth factor receptor tyrosine kinase inhibitor–resistant disease K Ohashi, YE Maruvka, F Michor, W Pao Journal of Clinical Oncology 31 (8), 1070, 2013 | 523 | 2013 |
| Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 K Ohashi, LV Sequist, ME Arcila, T Moran, J Chmielecki, YL Lin, Y Pan, ... Proceedings of the National Academy of Sciences 109 (31), E2127-E2133, 2012 | 509 | 2012 |
| Characteristics of Lung Cancers Harboring NRAS Mutations K Ohashi, LV Sequist, ME Arcila, CM Lovly, X Chen, CM Rudin, T Moran, ... Clinical Cancer Research 19 (9), 2584-2591, 2013 | 174 | 2013 |
| Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open … V Subbiah, J Wolf, B Konda, H Kang, A Spira, J Weiss, M Takeda, Y Ohe, ... The Lancet Oncology 23 (10), 1261-1273, 2022 | 167 | 2022 |
| A phase II study of trastuzumab emtansine in HER2-positive non–small cell lung cancer K Hotta, K Aoe, T Kozuki, K Ohashi, K Ninomiya, E Ichihara, T Kubo, ... Journal of Thoracic Oncology 13 (2), 273-279, 2018 | 141 | 2018 |
| Non–small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases H Isozaki, E Ichihara, N Takigawa, K Ohashi, N Ochi, M Yasugi, ... Cancer research 76 (6), 1506-1516, 2016 | 138 | 2016 |
| PL02. 08 registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers A Drilon, G Oxnard, L Wirth, B Besse, O Gautschi, SWD Tan, H Loong, ... Journal of Thoracic Oncology 14 (10), S6-S7, 2019 | 102 | 2019 |
| Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer M Tokumo, S Toyooka, S Ichihara, K Ohashi, K Tsukuda, K Ichimura, ... Lung cancer 53 (1), 117-121, 2006 | 74 | 2006 |
| Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo E Ichihara, K Ohashi, N Takigawa, M Osawa, A Ogino, M Tanimoto, ... Cancer research 69 (12), 5091-5098, 2009 | 71 | 2009 |
| Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and-resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with … P Jia, H Jin, CB Meador, J Xia, K Ohashi, L Liu, V Pirazzoli, KB Dahlman, ... Genome research 23 (9), 1434-1445, 2013 | 65 | 2013 |
| The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer H Watanabe, T Kubo, K Ninomiya, K Kudo, D Minami, E Murakami, N Ochi, ... Japanese journal of clinical oncology 49 (8), 762-765, 2019 | 54 | 2019 |
| JAK 2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation D Harada, N Takigawa, N Ochi, T Ninomiya, M Yasugi, T Kubo, H Takeda, ... Cancer science 103 (10), 1795-1802, 2012 | 53 | 2012 |
| NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor E Galvani, J Sun, LG Leon, R Sciarrillo, RS Narayan, RTT Sjin, K Lee, ... Oncotarget 6 (40), 42717, 2015 | 46 | 2015 |
| MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I J Brägelmann, C Lorenz, S Borchmann, K Nishii, J Wegner, L Meder, ... Nature communications 12 (1), 5505, 2021 | 38 | 2021 |
| MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib K Ninomiya, K Ohashi, G Makimoto, S Tomida, H Higo, H Kayatani, ... Scientific reports 8 (1), 1955, 2018 | 37 | 2018 |
